Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB6426 in Advanced Malignancies
NCT07730190Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB6426 in advanced cancer, sponsored by Chia Tai Tianqing. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
TQB6426
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT07730190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730190.